PTPRJ Antibody

說明書

中文名稱：

PTPRJ兔多克隆抗體
貨號：

CSB-PA613274ESR1HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human tonsil tissue using CSB-PA613274ESR1HU at dilution of 1:100

Immunohistochemistry of paraffin-embedded human lung cancer using CSB-PA613274ESR1HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) PTPRJ Polyclonal antibody
Uniprot No.：

Q12913
基因名：

PTPRJ
別名：

CD 148 antibody; CD148 antibody; CD148 antigen antibody; Density enhanced phosphatase 1 antibody; Density-enhanced phosphatase 1 antibody; DEP 1 antibody; DEP-1 antibody; HPTP eta antibody; HPTPeta antibody; Human density enhanced phosphatase 1 antibody; Protein tyrosine phosphatase eta antibody; Protein tyrosine phosphatase receptor type J antibody; Protein tyrosine phosphatase receptor type J polypeptide antibody; Protein-tyrosine phosphatase eta antibody; Protein-tyrosine phosphatase receptor type J antibody; PTPJ antibody; Ptprj antibody; PTPRJ_HUMAN antibody; R PTP Eta antibody; R-PTP-eta antibody; R-PTP-J antibody; Receptor type tyrosine protein phosphatase eta antibody; Receptor-type tyrosine-protein phosphatase eta antibody; SCC 1 antibody; SCC1 antibody; susceptibility to colon cancer 1; mouse; homolog of antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Receptor-type tyrosine-protein phosphatase eta protein (140-370AA)
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

Antigen Affinity Purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Tyrosine phosphatase which dephosphorylates or contributes to the dephosphorylation of CTNND1, FLT3, PDGFRB, MET, RET (variant MEN2A), KDR, LYN, SRC, MAPK1, MAPK3, EGFR, TJP1, OCLN, PIK3R1 and PIK3R2. Plays a role in cell adhesion, migration, proliferation and differentiation. Involved in vascular development. Regulator of macrophage adhesion and spreading. Positively affects cell-matrix adhesion. Positive regulator of platelet activation and thrombosis. Negative regulator of cell proliferation. Negative regulator of PDGF-stimulated cell migration; through dephosphorylation of PDGFR. Positive regulator of endothelial cell survival, as well as of VEGF-induced SRC and AKT activation; through KDR dephosphorylation. Negative regulator of EGFR signaling pathway; through EGFR dephosphorylation. Enhances the barrier function of epithelial junctions during reassembly. Negatively regulates T-cell receptor (TCR) signaling. Upon T-cell TCR activation, it is up-regulated and excluded from the immunological synapses, while upon T-cell-antigen presenting cells (APC) disengagement, it is no longer excluded and can dephosphorylate PLCG1 and LAT to down-regulate prolongation of signaling.
基因功能參考文獻：
1. PTPRJ variant of uncertain significance in candidate gene was identified in Familial Mitral Valve Prolapse. PMID: 29762926
2. Short variant of the receptor protein phosphatase PTPRJ generated by an alternative splicing promotes angiogenesis in HUVEC cells and tumor angiogenesis. PMID: 28052032
3. study reveals the crucial role of miR-155/PTPRJ/AKT axis in proliferation and migration of colorectal cancer cells and suggests a therapeutic potential of PTPRJ. PMID: 28316102
4. Authors demonstrate that mtp53 prevents the COP1/DET1 complex from ubiquitinating ETS2 and thereby marking it for destruction. Authors show that mtp53 destabilizes DET1 and also disrupts the DET1/ETS2 complex thereby preventing ETS2 degradation. PMID: 26871468
5. These data support that PTPN22 1858C/T, PTPRJ 2965C/G and 1176 A/C polymorphisms and ACP1 A, B and C alleles are not associated with a higher risk of immune thrombocytopenia P in adults. PMID: 27309885
6. Loss of PTPRJ expression may predict an aggressive clinical course in ESCC patients. PMID: 26694178
7. The strongest association with frailty was observed in the Protein Tyrosine Phosphatase, Receptor type, J (PTPRJ) (rs1566729, P = 0.001372, beta = 0.09397) gene. PMID: 26248682
8. the combination of CD200 and CD148 may have a potential differential diagnostic value in leukemic B-CLPDs, especially between CLL and MCL. PMID: 25791119
9. These results demonstrated Ptprj as a physiological enzyme that attenuates insulin signalling in vivo, and indicate that an inhibitor of Ptprj may be an insulin-sensitizing agent. PMID: 26063811
10. CD148 tyrosine phosphatase promotes e-cadherin cell adhesion. PMID: 25386896
11. The studies suggest induction of MMP-9 expression promoted by DEP-1 deficiency. PMID: 25672645
12. Moderate expression of DEP-1 was associated with the increased relapse. PMID: 25772245
13. C33A cells lacking PTPRJ had increased cell viability, growth, migration, G1-S transition, and 5-FU resistance. PTPRJ negatively regulated the JAK1/STAT3 pathway by decreasing phosphorylation levels of JAK1 and STAT3 and expression of downstream factors. PMID: 25634668
14. The expression profiles of DEP1 and B2MG correlate with increased cell senescence and survival in breast cancer. PMID: 25412306
15. Phosphorylation of T1318 is part of a regulatory mechanism that channels the activity of DEP-1 towards Src to allow its optimal activation and the promotion of endothelial cell permeability. PMID: 24583284
16. Data indicate that CD148 is upregulated in macrophages and T cells in rheumatoid arthritis (RA) samples, and its activity is enhanced by treatment with tumour necrosis factor alpha (TNFalpha), and reduced by synovial fluid or oxidising conditions. PMID: 24016860
17. our data support the notion of DEP-1 as positive functional regulator in vascular cerebral arteriogenesis, involving differential PDGF-B gene expression. PMID: 24027763
18. FLT3 is a bona fide substrate of DEP-1 and that interaction occurs mainly via an enzyme-substrate complex formation triggered by FLT3 ligand stimulation. PMID: 23650535
19. haplotypes in PTPRJ gene may play a role in susceptibility to Non-Hodgkin's lymphoma, by affecting activation of PTPRJ in these B-cell lymphomas. PMID: 23341091
20. Data indicate that miR-328 regulated PTPRJ expression, and suggest that the interaction of miR-328 with PTPRJ is responsible for miR-328-dependent increase of epithelial cell proliferation. PMID: 22564856
21. These data indicate that PTPRJ may regulate differentiation of normal mammary epithelia and that dysregulation of protein localisation may be associated with tumorigenesis. PMID: 22815804
22. CD148 polymorphisms affect platelet activation and probably exert a protective effect on the risk of Heparin-induced thrombocytopenia in patients with antibodies to PF4/Heparin complexes. PMID: 22677127
23. DEP-1 oxidation is a novel event contributing to cell transformation by FLT3 ITD. PMID: 22438257
24. These findings provide evidence that CD148 functions as a receptor for TSP1 and mediates its inhibition of cell growth. PMID: 22308318
25. Here the protein tyrosine phosphatase receptor CD148 is shown to be a key intermediary in cell adhesion to S2ED, with downstream beta1 integrin-mediated adhesion and cytoskeletal organization PMID: 21813734
26. We propose that positive regulation of adhesion signaling by DEP-1 is involved in inhibition of meningioma cell motility, and possibly tumor invasiveness. PMID: 21091576
27. differential effects of CD148 in T cells and other leukocyte subsets PMID: 21543337
28. That DEP-1 plays a biologic role in angiogenic endothelial cell behavior was demonstrated in endothelial cell migration, proliferation, and capillary-like tube formation assays in vitro PMID: 21304107
29. DEP-1 is negatively regulating FLT3 signaling activity and that its loss may contribute to but is not sufficient for leukemogenic cell transformation. PMID: 21262971
30. Therefore, the results reported here show that the homozygous genotype for Asp872 of PTPRJ is associated with an increased risk to develop papillary thyroid carcinoma. PMID: 20823296
31. PTPRJ is a candidate colorectal cancer susceptibility gene PMID: 21036128
32. DEP-1 is a tumor suppressor that dephosphorylates and thereby stabilizes EGFR by hampering its ability to associate with the CBL-GRB2 ubiquitin ligase complex. PMID: 19836242
33. PTPRJ SNPs were found to influence susceptibility to a wide spectrum of cancers. PMID: 19672627
34. This protein is frequently deleted in human breast cancers. PMID: 12089527
35. CD148 and CD27 are expressed in a wide range of B cell non-Hodgkin's lymphomas and do not serve to distinguish between neoplastic cells of naive and memory B cell derivation PMID: 12685844
36. DEP-1 is a negative regulator of cell proliferation, cell-substratum contacts, motility and chemotaxis in fibroblasts PMID: 14709717
37. propose that the expression and activation of DEP-1/PTPeta is required for somatostatin inhibition of glioma proliferation PMID: 15123617
38. A candidate tumor suppressor gene because its expression was blocked in rat and human thyroid transformed cells, and its restoration reverted their neoplastic phenotype. PMID: 15231692
39. genotypic profile of PTPRJ affects susceptibility to thyroid carcinomas, loss involved in thyroid carcinogenesis PMID: 15378013
40. single nucleotide polymorphisms in protein tyrosine phosphatase receptor type J is associated with breast cancer PMID: 16000320
41. Male, dizygotic twins were diagnosed with sensori-neural deafness at ages 5 and 21 months and later developed hypothyroidism at ages 24 and 28 months, respectively. Analysis for anti-DEP-1/CD148 autoantibodies described in Cogan syndrome proved positive. PMID: 16582570
42. Chemoprotective nutrients elevated transcription of endogenous DEP-1 mRNA & expression of DEP-1 protein. Upregulation of DEP-1 expression & inhibition of cell growth & migration may be a previously unrecognized mechanism of chemoprevention by nutrients. PMID: 16682945
43. These results demonstrate that CD148 may interact with and dephosphorylate p85 when it is phosphorylated and modulate the magnitude of phosphoinositide 3-kinase activity. PMID: 18348712
44. The translation of the region between AUG(191) and AUG(356) inhibits the overall expression of PTPRJ mRNA. PMID: 18603590
45. No significant evidence for the A1176C allele of PTPRJ or previously described haplotypes of tagSNPs in PTPRJ on CRC risk. PMID: 18843023
46. DEP-1 is a positive regulator of VEGF-mediated Src and Akt activation and endothelial cell survival. PMID: 18936167
47. The intact structure of the eighth fibronectin domain of PTPRJ is critical for its localization in plasma membrane and biological function. PMID: 19122201
48. DEP-1 can modify the phosphorylation state of tight junction proteins and play a role in regulating permeability. PMID: 19332538
49. CD148 may have a role in mantle cell lymphoma PMID: 19413345
50. In this paper, frequent deletion of PTPRJ is shown in human colon, lung, and breast cancers. PMID: 12089527
顯示更多

收起更多
亞細胞定位：

Cell membrane; Single-pass type I membrane protein. Cell projection, ruffle membrane. Cell junction. Note=After T-cell stimulation, it is temporarily excluded from immunological synapses.
蛋白家族：

Protein-tyrosine phosphatase family, Receptor class 3 subfamily
組織特異性：

Expressed in the promyelocytic cell line HL-60, the granulocyte-macrophage colony-stimulating factor-dependent leukemic cell line F-36P, and the IL3 and erythropoietin-dependent leukemic cell line F-36E. Expressed predominantly in epithelial cells and lym
數據庫鏈接：

HGNC: 9673

OMIM: 600925

KEGG: hsa:5795

STRING: 9606.ENSP00000400010

UniGene: Hs.318547

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human